EDIT
Editas Medicine, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Editas Medicine (EDIT) Stock: Buy, Sell, or Hold?
$2.51
-0.25 (-8.91%)
âŧ
5d:
-3.65%
30d:
-8.91%
90d:
-11.8%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (77%)
Quality Score
51/100
Position
SLIGHTLY LOW
30-Day Fair Range
$2.43 â $2.79
Position: SLIGHTLY LOW
Forward P/E & Valuation
-3.4x
Next 12M consensus est.
Wall Street Target
$6.10
+143.5% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$2.41 / $3.01
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: EDIT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When EDIT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: EDIT is currently trading at $2.50, which is considered slightly low relative to its 30-day fair value range of $2.43 to $2.79.
Technical Outlook: Technically, EDIT is in a strong uptrend. Immediate support is located at $2.41, while resistance sits at $3.00. Short-term momentum is weak, with the stock down 8.9% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.10 (+143.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EDIT is in a strong uptrend. Immediate support is located at $2.41, while resistance sits at $3.00. Short-term momentum is weak, with the stock down 8.9% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.10 (+143.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.43 -
$2.79
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
Trading Range & Key Levels
30-Day Trading Range
$2.43 -
$2.79
Current vs Trading Range
SLIGHTLY LOW
Support Level
$2.41
Resistance Level
$3.01
Current Trend
Strong Uptrend
Technical data as of
Nov 10, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.9%)
- BULLISH: Trading 143.5% below Wall St target ($6.10)
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-3.41
Wall Street Target
$6.10
(+143.5%)
Revenue Growth (YoY)
37.4%
Profit Margin
-144.9%
Share EDIT Analysis
Share this live EDIT analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (EDIT)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 31, 2026
Daily AI digest
AI Retail Discussion Summary:
StockTwits shows bullish sentiment towards $EDIT, with one user expecting a rebound after hours and a potential upward trend come Monday.
Key Retail Themes:
positive sentiment towards $EDIT
expectation of an upward trend
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 5:13 AM ET
Data refreshes hourly during market hours. Next update: 6:13 AM
Data refreshes hourly during market hours. Next update: 6:13 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EDIT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron PharmaceuticalâĻ |
BUY
28 analysts |
$978 | 37 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$296 | 43 HOLD |
|
NAMS
NewAmsterdam Pharma CompâĻ |
STRONG BUY
16 analysts |
$50 | 49 HOLD |
|
CGEM
Cullinan Oncology LLC |
STRONG BUY
12 analysts |
$35 | 57 HOLD |
|
NKTR
Nektar Therapeutics |
STRONG BUY
15 analysts |
$133 | 66 BUY |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive EDIT Research Pages
